A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Last updated: July 15, 2014
Sponsor: Astellas Pharma Inc
Overall Status: Completed

Phase

3

Condition

Kidney Failure

Nephropathy

Kidney Disease

Treatment

N/A

Clinical Study ID

NCT01742585
1585-CL-0101
  • Ages > 20
  • All Genders

Study Summary

This is a randomized, double blind, placebo-controlled multi-center study to examine the efficacy and safety of ASP1585 in chronic kidney disease patients with hyperphosphatemia not on dialysis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Chronic kidney disease patients (eGFR < 60 mL/min/1.73 m2)

  • Serum phosphorus measurement ≧4.6 mg/dl, <9.0 mg/dl

  • Written informed consent

Exclusion

Exclusion Criteria:

  • Patients with gastrointestinal surgery or enterectomy

  • Patients with severe cardiac diseases

  • Patients with severe constipation or diarrhea

  • Patients with a history or complication of malignant tumors

  • Patients with uncontrolled hypertension

  • Patients treated with parathyroid intervention within 6 months

Study Design

Total Participants: 163
Study Start date:
October 01, 2012
Estimated Completion Date:
May 31, 2014

Connect with a study center

  • Chubu,
    Japan

    Site Not Available

  • Hokkaido,
    Japan

    Site Not Available

  • Kansai,
    Japan

    Site Not Available

  • Kanto,
    Japan

    Site Not Available

  • Kyushu,
    Japan

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.